High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy

February 15, 2024 updated by: WANG KAI, Anhui Medical University

The Efficacy, Safety and Mechanism of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Refractory Epilepsy

To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.

Study Overview

Detailed Description

All participants underwent a medical evaluation that included physical examination and routine laboratory studies before and after high definition transcranial direct current stimulation (HD-tDCS) treatment.Upon meeting the inclusion criteria and providing informed consent, each participant will complete clinical assessments by a trained investigator and HD-tDCS treatment at Anhui mental health centre.

At least 90 participants were randomized (1:1:1) to receive "bilateral active" ,"Unilateral active" or "Sham" treatment protocol. The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .

In the bilateral treatment group, HD-tDCS treatment was placed on the left and right sides of the brain, at least eight hours apart. Twenty 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 30 minutes,twice a day over 10 consecutive workdays. In the unilateral treatment group, HD-tDCS treatment based on Epileptic discharge is placed on either the left or right side of the brain.Ten 2-mA sessions were applied for 30 minutes,once a day over 10 consecutive workdays.Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.

Before and after the tDCS treatment, the patients had receiving a battery measure of neuropsychological tests, Magnetic resonance imaging scan in multimodalities, VEEG and Resting motor threshold.

The clinical symptom of participants were followed 4 weeks and 12 weeks after the last treatment.

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Anhui
      • Hefei, Anhui, China
        • Recruiting
        • Anhui Medical University
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinical diagnosis of refractory epilepsy
  • Right-handed and aged 18-50 years old and primary school education or above;
  • No major neurological or mental illness, no head injury, alcohol dependence or drug dependence;
  • During the experiment, the subjects did not smoke, drink, get sick and take psychotropic drugs, and there were no major life events that caused mood changes.

Exclusion Criteria:

  • organic brain injury, neurological diseases or serious physical diseases;
  • Have a history of substance abuse and drug dependence, or have used antipsychotic drugs in the past three months, and have serious suicidal tendencies;
  • There are contraindications for MRI or EEG or transcranial magnetic stimulation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Unilateral real High definition transcranial direct current stimulation

The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .

In the unilateral treatment group, HD-tDCS treatment based on Epileptic discharge is placed on either the left or right side of the brain.Ten 2-mA sessions were applied for 30 minutes,once a day over 10 consecutive workdays.

Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed
Active Comparator: Bilateral real High definition transcranial direct current stimulation

The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .

In the bilateral treatment group, HD-tDCS treatment was placed on the left and right sides of the brain, at least eight hours apart.. Twenty 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 30 minutes,twice a day over 10 consecutive workdays.

Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed
Sham Comparator: Sham High definition transcranial direct current stimulation

The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10.

The 30 subjects were randomly divided into two groups, 15 receiving bilateral Sham HD-tDCS and 15 receiving unilateral Sham HD-tDCS.

Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.

The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes of Epilepsy diary
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The reduction of seizure frequency in patients with epilepsy will constitute the primary outcome measure to evaluate the efficacy of HD-tDCS, reflecting the improvement of patients' clinical symptoms. Patients and family members are asked to keep an epilepsy diary to record the time, duration, and status of the seizure.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes of VEEG
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The number of discharges recorded by VEEG before and after the intervention, as well as the decrease in epileptiform discharge index, were used as indicators to evaluate the improvement of epilepsy symptoms
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of resting-state functional connectivity
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
the change of resting-state functional connectivity strength between stimulated target and the whole brain areas will be measured by functional MRI and resting-state EEG.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of resting motor threshold(RMT)
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
Previous studies have found that the resting movement threshold is an effective measure of cortical excitability in epilepsy patients, and can better predict the therapeutic effect. An elevated resting movement threshold indicates that the treatment is responding.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of glutamate receptor-mediated intracortical facilitation (ICF)
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
ICF is a 120% RMT stimulation administered 15 ms after 90% RMT intensity stimulation, glutamate receptor-mediated intracortical promotion
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of GABA-A receptor-mediated short septal cortical inhibition (SICI)
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
SICI is 120% RMT administered 4 ms after 80% RMT intensity stimulation in response to GABA-A receptor-mediated short-interval cortical inhibition
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of GABA-B receptor-mediated long septal cortical inhibition (LICI).
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
LICI is 120% RMT administered 150ms after 120% RMT intensity stimulation in response to GABA-A receptor-mediated long-interval cortical inhibition,
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of Hamilton Depression Rating Scale (HAMD) Score
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The HAMD is a clinic ian-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of Hamilton Anxiety Scale (HAMA) Score
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The HAMA is a 14-item scale to measure the severity of anxiety symptoms, where each item is rated on a scale from 0 to 4. The HAMA total score ranges from 0 to 56, with lower scores indicating less anxiety symptoms.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of MoCA Score
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
MoCA was developed by Nasreddine et al. based on clinical experience and reference to the MMSE cognitive items and scores, and the final version was finalized in November 2004. We adopted a localized version (Mandarin version,includes 2 alternative versions) in line with the Chinese cultural background.A higher score indicates improvement
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of Chinese auditory learning test Score
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
A group consists of 15 words, read to the subject at a speed of one per second, after reading, let the patient repeat these 15 words, record the number of words spoken correctly, repeat the above behavior five times, start the timer after the end, let the patient recall 15 words after 30 minutes, and calculate the correct number,The more vocabulary is memorized, the better the score
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of TMT (Trail Making Test) Score
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The Trail Making Test (TMT) is divided into two parts, part A and part B. Part A requires the subject to connect 25 Numbers on the paper in sequence, and part B requires the subject to connect 25 Numbers of different colors alternately in sequence. The time it takes for the subject to complete all the Numbers is the subject's final score.the shorter the better.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The changes of Face associative memory Score
Time Frame: Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months
The associative memory was estimated using a face-cued word association test. In the face-cued word association test, participants studied 20 human face photographs presented individually in grayscale on a computer screen for 4 s per face. Each photograph displayed a unique common word that the participants read aloud as each face-word pair was shown. The participants were instructed to memorize the word associated with each face. After the face-word pairs were presented, participants were shown the same 20 faces, individually and in a different and randomized order. They were asked to recall the words that were presented with each face. Each face was scored as correct or incorrect. These processes are carried out 2 times in total. The average number of successful answers was defined as the associative memory score.The more faces you remember correctly, the higher your score.
Baseline and 10 workdays post-treatment,and follow-up to 1 months and 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 12, 2024

Primary Completion (Estimated)

December 30, 2025

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

January 4, 2024

First Submitted That Met QC Criteria

January 24, 2024

First Posted (Actual)

February 5, 2024

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 15, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Transcranial Magnetic Stimulation

Clinical Trials on Active Comparator: Unilateral real High definition transcranial direct current stimulation

3
Subscribe